{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:22:48Z","timestamp":1790706168196,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T00:00:00Z","timestamp":1634256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T00:00:00Z","timestamp":1634256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s00259-021-05568-w","type":"journal-article","created":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T06:41:59Z","timestamp":1634280119000},"page":"1263-1274","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Added value of semiquantitative analysis of brain FDG-PET for the differentiation between MCI-Lewy bodies and MCI due to Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5667-204X","authenticated-orcid":false,"given":"Federico","family":"Massa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Chincarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bauckneht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Raffa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Peira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Arnaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Pardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Pagani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Orso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Isabella","family":"Donegani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Brugnolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Biassoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Mattioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Girtler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo Paolo","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Morbelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Nobili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,15]]},"reference":[{"key":"5568_CR1","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/ene.14117","volume":"27","author":"M Boccardi","year":"2020","unstructured":"Boccardi M, Nicolosi V, Festari C, et al. Italian consensus recommendations for a biomarker-based aetiological diagnosis in mild cognitive impairment patients. Eur J Neurol. 2020;27:475\u201383.","journal-title":"Eur J Neurol"},{"key":"5568_CR2","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1111\/ene.13728","volume":"25","author":"F Nobili","year":"2018","unstructured":"Nobili F, Arbizu J, Bouwman F, et al. European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18 F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. Eur J Neurol. 2018;25:1201\u201317.","journal-title":"Eur J Neurol"},{"key":"5568_CR3","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S1474-4422(20)30314-8","volume":"19","author":"G Ch\u00e9telat","year":"2020","unstructured":"Ch\u00e9telat G, Arbizu J, Barthel H, et al. Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer\u2019s disease and other dementias. Lancet Neurol. 2020;19:951\u201362.","journal-title":"Lancet Neurol"},{"key":"5568_CR4","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/ana.1133","volume":"50","author":"S Minoshima","year":"2001","unstructured":"Minoshima S, Foster NL, Sima AAF, Frey KA, Albin RL, Kuhl DE. Alzheimer\u2019s disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol. 2001;50:358\u201365.","journal-title":"Ann Neurol"},{"key":"5568_CR5","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.2967\/jnumed.114.143347","volume":"55","author":"JT O\u2019Brien","year":"2014","unstructured":"O\u2019Brien JT, Firbank MJ, Davison C, et al. 18F-FDG PET and perfusion SPECT in the diagnosis of Alzheimer and Lewy body dementias. J Nucl Med. 2014;55:1959\u201365.","journal-title":"J Nucl Med"},{"key":"5568_CR6","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1007\/s00259-007-0380-y","volume":"34","author":"AK Kono","year":"2007","unstructured":"Kono AK, Ishii K, Sofue K, Miyamoto N, Sakamoto S, Mori E. Fully automatic differential diagnosis system for dementia with Lewy bodies and Alzheimer\u2019s disease using FDG-PET and 3D-SSP. Eur J Nucl Med Mol Imaging. 2007;34:1490\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5568_CR7","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.2967\/jnumed.109.065870","volume":"50","author":"ML Seok","year":"2009","unstructured":"Seok ML, Katsifis A, Villemagne VL, et al. The 18F-FDG PET cingulate island sign and comparison to 123I-\u03b2-CIT SPECT for diagnosis of dementia with Lewy bodies. J Nucl Med. 2009;50:1638\u201345.","journal-title":"J Nucl Med"},{"key":"5568_CR8","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.nicl.2014.10.009","volume":"6","author":"D Perani","year":"2014","unstructured":"Perani D, Della Rosa PA, Cerami C, et al. Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting. NeuroImage Clin. 2014;6:445\u201354.","journal-title":"NeuroImage Clin"},{"key":"5568_CR9","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1192\/bjp.bp.114.160804","volume":"208","author":"MJ Firbank","year":"2016","unstructured":"Firbank MJ, Lloyd J, Williams D, et al. An evidence-based algorithm for the utility of FDG-PET for diagnosing Alzheimer\u2019s disease according to presence of medial temporal lobe atrophy. Br J Psychiatry. 2016;208:491\u20136.","journal-title":"Br J Psychiatry"},{"key":"5568_CR10","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies. Neurology. 2017;89:88\u2013100.","journal-title":"Neurology"},{"key":"5568_CR11","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/ana.25453","volume":"85","author":"S Morbelli","year":"2019","unstructured":"Morbelli S, Chincarini A, Brendel M, et al. Metabolic patterns across core features in dementia with Lewy bodies. Ann Neurol. 2019;85:715\u201325.","journal-title":"Ann Neurol"},{"key":"5568_CR12","doi-asserted-by":"crossref","unstructured":"Kantarci K, Boeve BF, Przybelski SA, et al. FDG PET metabolic signatures distinguishing prodromal DLB and prodromal AD. NeuroImage Clin. 2021;31:102754.","DOI":"10.1016\/j.nicl.2021.102754"},{"key":"5568_CR13","doi-asserted-by":"crossref","unstructured":"Bauckneht M, Chincarini A, Brendel M, et al. Associations among education, age, and the dementia with Lewy bodies (DLB) metabolic pattern: a European-DLB consortium project. Alzheimer\u2019s Dement. 2021.","DOI":"10.1002\/alz.12294"},{"key":"5568_CR14","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1212\/WNL.0000000000009323","volume":"94","author":"IG McKeith","year":"2020","unstructured":"McKeith IG, Ferman TJ, Thomas AJ, et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology. 2020;94:743\u201355.","journal-title":"Neurology"},{"key":"5568_CR15","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1136\/jnnp-2017-316844","volume":"89","author":"G Rizzo","year":"2018","unstructured":"Rizzo G, Arcuti S, Copetti M, et al. Accuracy of clinical diagnosis of dementia with Lewy bodies: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2018;89:358\u201366.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"5568_CR16","first-page":"646","volume":"53","author":"F Clerici","year":"2009","unstructured":"Clerici F, Del Sole A, Chiti A, et al. Differences in hippocampal metabolism between amnestic and non-amnestic MCI subjects: automated FDG-PET image analysis. Q J Nucl Med Mol Imaging. 2009;53:646\u201357.","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"5568_CR17","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.nicl.2014.12.004","volume":"7","author":"C Cerami","year":"2015","unstructured":"Cerami C, Della Rosa PA, Magnani G, et al. Brain metabolic maps in mild cognitive impairment predict heterogeneity of progression to dementia. NeuroImage Clin. 2015;7:187\u201394.","journal-title":"NeuroImage Clin"},{"key":"5568_CR18","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1007\/s00259-018-4039-7","volume":"45","author":"J Arbizu","year":"2018","unstructured":"Arbizu J, Festari C, Altomare D, et al. Clinical utility of FDG-PET for the clinical diagnosis in MCI. Eur J Nucl Med Mol Imaging. 2018;45:1497\u2013508.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5568_CR19","doi-asserted-by":"publisher","first-page":"815","DOI":"10.3233\/JAD-142229","volume":"44","author":"S Morbelli","year":"2015","unstructured":"Morbelli S, Brugnolo A, Bossert I, et al. Visual versus semi-quantitative analysis of 18F-FDG-PET in amnestic MCI: an European Alzheimer\u2019s Disease Consortium (EADC) Project. J Alzheimer\u2019s Dis. 2015;44:815\u201326.","journal-title":"J Alzheimer\u2019s Dis"},{"key":"5568_CR20","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1007\/s00259-018-4030-3","volume":"45","author":"F Nobili","year":"2018","unstructured":"Nobili F, Festari C, Altomare D, et al. Automated assessment of FDG-PET for differential diagnosis in patients with neurodegenerative disorders. Eur J Nucl Med Mol Imaging. 2018;45:1557\u201366.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5568_CR21","doi-asserted-by":"publisher","first-page":"632","DOI":"10.2967\/jnumed.116.179903","volume":"58","author":"JL Whitwell","year":"2017","unstructured":"Whitwell JL, Graff-Radford J, Singh TD, et al. 18 F-FDG PET in posterior cortical atrophy and dementia with Lewy bodies. J Nucl Med. 2017;58:632\u20138.","journal-title":"J Nucl Med"},{"key":"5568_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-018-0453-0","volume":"11","author":"SP Caminiti","year":"2019","unstructured":"Caminiti SP, Sala A, Iaccarino L, et al. Brain glucose metabolism in Lewy body dementia: implications for diagnostic criteria. Alzheimer\u2019s Res Ther. 2019;11:1\u201314.","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"5568_CR23","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1212\/WNL.0000000000004826","volume":"90","author":"RC Petersen","year":"2018","unstructured":"Petersen RC, Lopez O, Armstrong MJ, et al. Practice guideline update summary: mild cognitive impairment report of the guideline development, dissemination, and implementation. Neurology. 2018;90:126\u201335.","journal-title":"Neurology"},{"key":"5568_CR24","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2011;7:270\u20139.","journal-title":"Alzheimer\u2019s Dement"},{"key":"5568_CR25","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1161\/01.STR.32.6.1318","volume":"32","author":"LO Wahlund","year":"2001","unstructured":"Wahlund LO, Barkhof F, Fazekas F, et al. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke. 2001;32:1318\u201322.","journal-title":"Stroke"},{"key":"5568_CR26","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1007\/s00259-009-1264-0","volume":"36","author":"A Varrone","year":"2009","unstructured":"Varrone A, Asenbaum S, Vander Borght T, et al. EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur J Nucl Med Mol Imaging. 2009;36:2103\u201310.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5568_CR27","doi-asserted-by":"crossref","unstructured":"Massa F, Grisanti S, Brugnolo A, et al. The role of anterior prefrontal cortex in prospective memory: an exploratory FDG-PET study in early Alzheimer{\u2019}s disease. Neurobiol Aging. 2020.","DOI":"10.1016\/j.neurobiolaging.2020.09.003"},{"key":"5568_CR28","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1002\/hbm.20718","volume":"30","author":"SB Eickhoff","year":"2009","unstructured":"Eickhoff SB, Laird AR, Grefkes C, Wang LE, Zilles K, Fox PT. Coordinate-based activation likelihood estimation meta-analysis of neuroimaging data: a random-effects approach based on empirical estimates of spatial uncertainty. Hum Brain Mapp. 2009;30:2907\u201326.","journal-title":"Hum Brain Mapp"},{"key":"5568_CR29","doi-asserted-by":"crossref","unstructured":"Lancaster JL, Woldorff MG, Parsons LM, et al. Automated Talairach atlas labels for functional brain mapping. Vol 10.; 2000.","DOI":"10.1002\/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8"},{"key":"5568_CR30","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S1474-4422(07)70057-1","volume":"6","author":"I McKeith","year":"2007","unstructured":"McKeith I, O\u2019Brien J, Walker Z, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 2007;6:305\u201313.","journal-title":"Lancet Neurol"},{"key":"5568_CR31","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1212\/WNL.0000000000003512","volume":"88","author":"AJ Thomas","year":"2017","unstructured":"Thomas AJ, Attems J, Colloby SJ, et al. Autopsy validation of 123 I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB. Neurology. 2017;88:276\u201383.","journal-title":"Neurology"},{"key":"5568_CR32","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1017\/S0033291718000995","volume":"49","author":"AJ Thomas","year":"2019","unstructured":"Thomas AJ, Donaghy P, Roberts G, et al. Diagnostic accuracy of dopaminergic imaging in prodromal dementia with Lewy bodies. Psychol Med. 2019;49:396\u2013402.","journal-title":"Psychol Med"},{"key":"5568_CR33","doi-asserted-by":"crossref","unstructured":"Perra D, Bongianni M, Novi G, et al. Alpha-synuclein seeds in olfactory mucosa and cerebrospinal fluid of patients with dementia with Lewy bodies. Brain Commun. 2021;3.","DOI":"10.1093\/braincomms\/fcab045"},{"key":"5568_CR34","doi-asserted-by":"crossref","unstructured":"Pagani M, De Carli F, Morbelli S, et al. Volume of interest-based [18F]fluorodeoxyglucose PET discriminates MCI converting to Alzheimer\u2019s disease from healthy controls. A European Alzheimer\u2019s Disease Consortium (EADC) study. NeuroImage Clin. 2015;7:34\u201342.","DOI":"10.1016\/j.nicl.2014.11.007"},{"key":"5568_CR35","doi-asserted-by":"publisher","first-page":"383","DOI":"10.3233\/JAD-181022","volume":"68","author":"A Brugnolo","year":"2019","unstructured":"Brugnolo A, De Carli F, Pagani M, et al. Head-to-head comparison among semi-quantification tools of brain FDG-PET to aid the diagnosis of prodromal Alzheimer\u2019s disease. J Alzheimer\u2019s Dis. 2019;68:383\u201394.","journal-title":"J Alzheimer\u2019s Dis"},{"key":"5568_CR36","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1212\/WNL.51.1.125","volume":"51","author":"K Ishii","year":"1998","unstructured":"Ishii K, Imamura T, Sasaki M, et al. Regional cerebral glucose metabolism in dementia with lewy bodies and Alzheimer\u2019s disease. Neurology. 1998;51:125\u201330.","journal-title":"Neurology"},{"key":"5568_CR37","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1006\/exnr.2000.7342","volume":"162","author":"M Higuchi","year":"2000","unstructured":"Higuchi M, Tashiro M, Arai H, et al. Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies. Exp Neurol. 2000;162:247\u201356.","journal-title":"Exp Neurol"},{"key":"5568_CR38","doi-asserted-by":"publisher","first-page":"704","DOI":"10.2967\/jnumed.106.035691","volume":"48","author":"K Ishii","year":"2007","unstructured":"Ishii K, Soma T, Kono AK, et al. Comparison of regional brain volume and glucose metabolism between patients with mild dementia with Lewy bodies and those with mild Alzheimer\u2019s disease. J Nucl Med. 2007;48:704\u201311.","journal-title":"J Nucl Med"},{"key":"5568_CR39","doi-asserted-by":"crossref","unstructured":"Bauckneht M, Chincarini A, Piva R, et al. Metabolic correlates of reserve and resilience in MCI due to Alzheimer\u2019s Disease (AD) Rik Ossenkoppele. Alzheimer\u2019s Res Ther. 2018;10.","DOI":"10.1186\/s13195-018-0366-y"},{"key":"5568_CR40","doi-asserted-by":"crossref","unstructured":"Gjerum L, Frederiksen KS, Henriksen OM, et al. A visual rating scale for cingulate island sign on 18F-FDG-PET to differentiate dementia with Lewy bodies and Alzheimer\u2019s disease. J Neurol Sci. 2020;410:116645.","DOI":"10.1016\/j.jns.2019.116645"},{"key":"5568_CR41","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/mds.25048","volume":"27","author":"SN Gomperts","year":"2012","unstructured":"Gomperts SN, Locascio JJ, Marquie M, et al. Brain amyloid and cognition in Lewy body diseases. Mov Disord. 2012;27:965\u201373.","journal-title":"Mov Disord"},{"key":"5568_CR42","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.jagp.2019.12.009","volume":"28","author":"PC Donaghy","year":"2020","unstructured":"Donaghy PC, Firbank MJ, Thomas AJ, et al. Amyloid imaging and longitudinal clinical progression in dementia with Lewy bodies. Am J Geriatr Psychiatry. 2020;28:573\u20137.","journal-title":"Am J Geriatr Psychiatry"},{"key":"5568_CR43","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1136\/jnnp-2016-313775","volume":"88","author":"AW Lemstra","year":"2017","unstructured":"Lemstra AW, De Beer MH, Teunissen CE, et al. Concomitant AD pathology affects clinical manifestation and survival in dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2017;88:113\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"5568_CR44","doi-asserted-by":"crossref","unstructured":"Kantarci K, Lowe VJ, Chen Q, et al. \u03b2-Amyloid PET and neuropathology in dementia with Lewy bodies. Neurology. 2020;94:e282-e291.","DOI":"10.1212\/WNL.0000000000008818"},{"key":"5568_CR45","doi-asserted-by":"crossref","unstructured":"Etminani K, Soliman A, Davidsson A, et al. A 3D deep learning model to predict the diagnosis of dementia with Lewy bodies, Alzheimer\u2019s disease, and mild cognitive impairment using brain 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2021.","DOI":"10.1007\/s00259-021-05483-0"},{"key":"5568_CR46","doi-asserted-by":"publisher","unstructured":"Twohig, D, Nielsen HM (2019) \u03b1-synuclein in the pathophysiology of Alzheimer\u2019s disease. Molecular Neurodegeneration 14(1) https:\/\/doi.org\/10.1186\/s13024-019-0320-x","DOI":"10.1186\/s13024-019-0320-x"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-021-05568-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-021-05568-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-021-05568-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T10:04:30Z","timestamp":1647252270000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-021-05568-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,15]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["5568"],"URL":"https:\/\/doi.org\/10.1007\/s00259-021-05568-w","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,15]]},"assertion":[{"value":"18 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures were performed in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. An institutional review board statement was not necessary because we merely used data collected during clinical routine and no other supplementary examinations were performed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study. All subjects gave their consent to publish their anonymized data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent and consent for publication"}},{"value":"Silvia Morbelli has received speaker Honoraria from G.E. Healthcare; Dario Arnaldi received fees from Fidia for lectures and board participation; Matteo Pardini receives research support from Novartis and Nutricia; received fees from Novartis, Merck, and Biogen; and is partly supported by a University of Genoa \u201ccuriosity-driven\u201d grant; Flavio Nobili has received fees for participating in boards from Roche, and speaker Honoraria from Bial e G.E. Healthcare. The other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}